HepaRegeniX develops a new and unique therapeutic concept to combat multiple liver diseases.
Find out more
Science
HepaRegeniX aims at curing liver diseases by reversing the disease path through liver regeneration. Along this path, the company is actively developing novel therapies for the treatment of both acute and chronic liver diseases.
Latest Press Releases
HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration
Tuebingen, Germany, April 15, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, today announced the second closing and completion of a €21.5 million financing round with the addition of Wellington Partners to its investor syndicate. HepaRegeniX plans to use the proceeds to complete its ongoingContinue reading "HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration"
HepaRegeniX appoints Dr. Martin Bonde as new Chair of the Board
Elias Papatheodorou moves from Chair of Board to CEO and Managing Director of HepaRegeniX Preparations for upcoming clinical trials in the USA are ongoing Tuebingen (Germany), October 22, 2024 – HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, today announced the appointment of Dr.Continue reading "HepaRegeniX appoints Dr. Martin Bonde as new Chair of the Board"